1
Paul O Zamora, Buck A Rhodes: Peptide-metal ion pharmaceutical preparation and method. Rhomed Incorporated, Deborah A Peacock, August 22, 1995: US05443816 (84 worldwide citation)

Peptides containing a biological-function domain and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologic conditions. The peptides have the amino acid sequence


2
Buck A Rhodes: Direct radiolabeling of antibodies and other proteins with technetium or rhenium. RhoMed Incorporated, Deborah A Peacock, April 7, 1992: US05102990 (67 worldwide citation)

Proteins containing one or more disulfide bonds are radiolabeled with radionuclides of technetium or rhenium for use in diagnosis and treatment of a variety of pathologic conditions. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the protein using Sn (II), or using othe ...


3
Shubh D Sharma: Peptide-metal ion pharmaceutical constructs and applications. Rhomed Incorporated, April 6, 1999: US05891418 (47 worldwide citation)

A peptide is provided for use as a diagnostic imaging, radiotherapeutic, or therapeutic agent, which peptide has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide is of the general formula:


4
Buck A Rhodes, Paul O Zamora: Direct labeling of antibodies and other protein with metal ions. RhoMed Incorporated, Deborah A Peacock, October 24, 1995: US05460785 (37 worldwide citation)

Proteins containing one or more dtsulfide bonds or monosulfides are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologtc conditions. Labeling is accomplished with a variety of metals, including radiometals, by using a reducing agent to reduce the dis ...


5
Buck A Rhodes: Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction. RhoMed Incorporated, Deborah A Peacock, January 7, 1992: US05078985 (35 worldwide citation)

Proteins are radiolabeled with radionuclides of technetium or rhenium by a process in which the disulfide bonds of the protein are first partially reduced with stannous salts or other disulfide reducing agents, all substances other than the desired reduced protein removed, by size exclusion chromato ...


6
Buck A Rhodes, Paul O Zamora, Richard J Freer, Shubh D Sharma: Polyvalent peptide pharmaceutical applications. Rhomed Incorporated, Darby & Darby, June 2, 1998: US05759515 (31 worldwide citation)

High affinity linked, branched or linear repeat peptides containing two or more biological-function domains and at least one medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, including diagnosis and trea ...


7
Buck A Rhodes: In vivo lymphocyte tagging. RhoMed Incorporated, Deborah A Peacock, Donovan F Duggan, January 11, 1994: US05277892 (25 worldwide citation)

Methods and reagents for the in vivo tagging of leukocytes, and in particular lymphocytes with a leukostimulatory agent and a linked medically useful metal ion, including a radioisotope, and subsequent detection of leukocyte or lymphocyte trafficking and sites of concentrated leukocytes or lymp


8
Paul O Zamora: Peptides method for radiolabeling them, and method for detecting inflammation. Rhomed Incorporated, Darby & Darby, September 23, 1997: US05670133 (22 worldwide citation)

High affinity chemotactic peptides containing a biological-function domain and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in diagnosis and treatment of infections, inflammations and related conditions.


9
Shubh D Sharma: Structurally determined metallo-constructs and applications. RhoMed Incorporated, Stephen A Slusher, John C Todaro, Deborah A Peacock, February 22, 2000: US06027711 (21 worldwide citation)

A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexin ...


10
Paul O Zamora, Michael J Merek: Post-labeling stabilization of radiolabeled proteins and peptides. RhoMed Incorporated, Darby & Darby, May 23, 2000: US06066309 (13 worldwide citation)

The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient admi ...